Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion -- Submission 2 of 2 (scRNA/CITE-seq)
Single-cell RNA-seq · human · 12 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 12 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE345979_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1522664 and SRA study SRP733167. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 12 sample titles: 12 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM10020330 ALLO715 10x Chromium 5' HT CITE-seq, ADT library
- GSM10020331 ALLO715 10x Chromium 5' HT CITE-seq, GEX library
- GSM10020332 ALLO715 10x Chromium 5' HT CITE-seq, TCR library
- GSM10020333 Cema_cel_Lot1 10x Chromium 5' HT CITE-seq, ADT library
- GSM10020334 Cema_cel_Lot1 10x Chromium 5' HT CITE-seq, GEX library
- GSM10020335 Cema_cel_Lot1 10x Chromium 5' HT CITE-seq, TCR library
- GSM10020336 Cema_cel_Lot1_AP 10x Chromium 5' HT CITE-seq, ADT library
- GSM10020337 Cema_cel_Lot1_AP 10x Chromium 5' HT CITE-seq, GEX library
- GSM10020338 Cema_cel_Lot1_AP 10x Chromium 5' HT CITE-seq, TCR library
- GSM10020339 Cema_cel_Lot2 10x Chromium 5' HT CITE-seq, ADT library
- GSM10020340 Cema_cel_Lot2 10x Chromium 5' HT CITE-seq, GEX library
- GSM10020341 Cema_cel_Lot2 10x Chromium 5' HT CITE-seq, TCR library
- GSE318420 Immunosuppressive monocytes are enriched in hepatocellular carcinoma patients with liver dysfunction in a phase II trial of combination sorafenib and nivolumab 210 samples shares car, cellular
- GSE235863 T cell populations correlate with response and resistance to anti-PD-1 plus lenvatinib combination therapy in hepatocellular carcinoma 69 samples shares car, cellular
- GSE272348 Late-stage tertiary lymphoid structures in hepatocellular carcinoma treated with neoadjuvant immune checkpoint blockade 31 samples shares car, cellular
- GSE14520 Gene expression data of human hepatocellular carcinoma (HCC) 488 samples shares car, cellular
- GSE109211 Molecular predictors of prevention of recurrence in hepatocellular carcinoma with sorafenib as adjuvant treatment in the phase 3 STORM trial 140 samples shares car, cellular
- GSE285963 Transcriptome profile of hepatocellular carcinoma in patients with atezolizumab plus bevacizumab therapy. 84 samples shares car, cellular
- GSE231854 The heterogeneity analysis of hepatocellular carcinoma and combined hepatocellular cholangiocarcinoma 81 samples shares car, cellular
- GSE302495 Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration 70 samples shares car, cellular
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.